Phase I study of recombinant human interferon alpha-2C in patients with chemotherapy-refractory malignancies.

Autor: Janssen JT, Ludwig H, Scheithauer W, de Pauw BE, Keyser A, van Tol R, Flener R
Jazyk: angličtina
Zdroj: Oncology [Oncology] 1985; Vol. 42 Suppl 1, pp. 3-6.
DOI: 10.1159/000226075
Abstrakt: Twenty-two patients with advanced haemopoietic and other malignancies were treated intramuscularly with recombinant interferon-alpha 2C in a daily escalating dose. The most common side-effects were flu-like symptoms. Two patients showed severe neurotoxicity, which was completely reversible in 1 case. Doses above 30 X 10(6) IU/day were poorly tolerated and could only be achieved in a minority of the patients. Objective tumour responses were documented in malignant lymphomas, hairy cell leukaemia, and renal cell carcinoma.
Databáze: MEDLINE